MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596223 | Name: Galanthamine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Galanthamine is a potent acetylcholinesterase (AChE) inhibitor with IC50 of 500 nM.

Chemical Structure

Galanthamine
Galanthamine
CAS#357-70-0 (free base)

Theoretical Analysis

MedKoo Cat#: 596223

Name: Galanthamine

CAS#: 357-70-0 (free base)

Chemical Formula: C17H21NO3

Exact Mass: 287.1521

Molecular Weight: 287.35

Elemental Analysis: C, 71.06; H, 7.37; N, 4.87; O, 16.70

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 Weeks
25mg USD 650.00 2 Weeks
50mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1953-04-4 (HBr) 357-70-0 (free base)
Synonym
Galanthamine; Galantamina; Galantamin; (-)-Galanthamine; (-)-Galantamine; Reminyl; Lycoremin; Lycoremine; NSC 100058; NSC100058; NSC-100058;
IUPAC/Chemical Name
(4aS,6R,8aS)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol
InChi Key
ASUTZQLVASHGKV-JDFRZJQESA-N
InChi Code
InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
SMILES Code
O[C@H]1C=C[C@@]23CCN(C)CC4=CC=C(OC)C(O[C@@]3([H])C1)=C24
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 287.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule M, Shoyele SA, Alexander A. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release. 2018 May 14. pii: S0168-3659(18)30268-2. doi: 10.1016/j.jconrel.2018.05.011. [Epub ahead of print] Review. PubMed PMID: 29772289. 2: Hsu WY, Lane HY, Lin CH. Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease. Front Psychiatry. 2018 Apr 4;9:91. doi: 10.3389/fpsyt.2018.00091. eCollection 2018. Review. PubMed PMID: 29670547; PubMed Central PMCID: PMC5893641. 3: Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H. Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Mar 19;3:CD000207. doi: 10.1002/14651858.CD000207.pub2. Review. PubMed PMID: 29553158. 4: Mezeiova E, Spilovska K, Nepovimova E, Gorecki L, Soukup O, Dolezal R, Malinak D, Janockova J, Jun D, Kuca K, Korabecny J. Profiling donepezil template into multipotent hybrids with antioxidant properties. J Enzyme Inhib Med Chem. 2018 Dec;33(1):583-606. doi: 10.1080/14756366.2018.1443326. Review. PubMed PMID: 29529892. 5: Kalász H, Ojha S, Tekes K, Szőke É, Mohanraj R, Fahim M, Adeghate E, Adem A. Pharmacognostical Sources of Popular Medicine To Treat Alzheimer's Disease. Open Med Chem J. 2018 Feb 16;12:23-35. doi: 10.2174/1874104501812010023. eCollection 2018. Review. PubMed PMID: 29515678; PubMed Central PMCID: PMC5827296. 6: Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine. Ther Adv Drug Saf. 2018 Mar;9(3):171-178. doi: 10.1177/2042098617750555. Epub 2018 Jan 8. Review. PubMed PMID: 29492246; PubMed Central PMCID: PMC5810854. 7: Gómez-Coronado N, Walker AJ, Berk M, Dodd S. Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking. Pharmacotherapy. 2018 Feb;38(2):235-258. doi: 10.1002/phar.2073. Epub 2018 Jan 29. Review. PubMed PMID: 29250815. 8: Sahoo AK, Dandapat J, Dash UC, Kanhar S. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease. J Ethnopharmacol. 2018 Apr 6;215:42-73. doi: 10.1016/j.jep.2017.12.015. Epub 2017 Dec 14. Review. PubMed PMID: 29248451. 9: May BH, Feng M, Hyde AJ, Hügel H, Chang SY, Dong L, Guo X, Zhang AL, Lu C, Xue CC. Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes. Int J Geriatr Psychiatry. 2018 Mar;33(3):449-458. doi: 10.1002/gps.4830. Epub 2017 Dec 14. Review. PubMed PMID: 29239495. 10: Seo EJ, Fischer N, Efferth T. Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer's disease. Pharmacol Res. 2018 Mar;129:262-273. doi: 10.1016/j.phrs.2017.11.030. Epub 2017 Nov 24. Review. PubMed PMID: 29179999. 11: Hiremathad A, Piemontese L. Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy. Neural Regen Res. 2017 Aug;12(8):1256-1261. doi: 10.4103/1673-5374.213541. Review. PubMed PMID: 28966636; PubMed Central PMCID: PMC5607816. 12: Kim SH, Kandiah N, Hsu JL, Suthisisang C, Udommongkol C, Dash A. Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease. Br J Pharmacol. 2017 Dec;174(23):4224-4232. doi: 10.1111/bph.14030. Epub 2017 Oct 29. Review. PubMed PMID: 28901528; PubMed Central PMCID: PMC5715569. 13: Swedish Council on Health Technology Assessment. Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet]. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK447961/ PubMed PMID: 28876770. 14: Glynn-Servedio BE, Ranola TS. AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's Disease. Consult Pharm. 2017 Sep 1;32(9):511-518. doi: 10.4140/TCP.n.2017.511. Review. PubMed PMID: 28855009. 15: Mehta N, Rodrigues C, Lamba M, Wu W, Bronskill SE, Herrmann N, Gill SS, Chan AW, Mason R, Day S, Gurwitz JH, Rochon PA. Systematic Review of Sex-Specific Reporting of Data: Cholinesterase Inhibitor Example. J Am Geriatr Soc. 2017 Oct;65(10):2213-2219. doi: 10.1111/jgs.15020. Epub 2017 Aug 18. Review. PubMed PMID: 28832937. 16: Prinsloo G, Marokane CK, Street RA. Anti-HIV activity of southern African plants: Current developments, phytochemistry and future research. J Ethnopharmacol. 2018 Jan 10;210:133-155. doi: 10.1016/j.jep.2017.08.005. Epub 2017 Aug 12. Review. PubMed PMID: 28807850. 17: Farooq MU, Min J, Goshgarian C, Gorelick PB. Pharmacotherapy for Vascular Cognitive Impairment. CNS Drugs. 2017 Sep;31(9):759-776. doi: 10.1007/s40263-017-0459-3. Review. PubMed PMID: 28786085. 18: Euwema MS, Swanson TJ. Toxicity, Deadly Single Dose Agents. 2017 Oct 6. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK441849/ PubMed PMID: 28722879. 19: Ramsay RR, Tipton KF. Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs. Molecules. 2017 Jul 15;22(7). pii: E1192. doi: 10.3390/molecules22071192. Review. PubMed PMID: 28714881. 20: Zanforlin E, Zagotto G, Ribaudo G. An Overview of New Possible Treatments of Alzheimer's Disease, Based on Natural Products and Semi-Synthetic Compounds. Curr Med Chem. 2017 Nov 17;24(34):3749-3773. doi: 10.2174/0929867324666170712161829. Review. PubMed PMID: 28707586.